Related Experiment Videos
Magnesium inhibits platelet activity--an in vitro study
H B Ravn1, H Vissinger, S D Kristensen
1Department of Internal Medicine and Cardiology, Aarhus Amtssygehus, Aarhus University Hospital, Denmark.
Abstract:
The in vitro effect of magnesium (Mg) on platelet aggregation and platelet release function was evaluated in healthy volunteers. Platelet aggregation was induced with collagen, ADP, or thrombin after incubation of the sample with saline or increasing concentrations of magnesium sulphate (MgSO4) (0.5-8.0 mM). Mg showed a dose-dependent inhibition of platelet aggregation in whole blood, platelet rich plasma and washed platelets. An antiaggregatory effect was also present with low Mg concentrations. Statistically significant inhibition of the mean aggregation response was obtained in 83% of the different media and agonists tested following the addition of 1.0 mM Mg. The remaining 17% were significantly inhibited with the addition of 2.0 mM Mg. The platelet synthesis of thromboxane A2 and release of beta-thromboglobulin were also inhibited by Mg, in a dose-dependent manner. In order to evaluate if any of these effects were modified by conventional antithrombotic treatment with low-dose acetylsalicylic acid (ASA), volunteers were asked to meet on two consecutive days. On day 2 the participants were given 300 mg ASA orally, one hour prior to blood sampling. The Mg mediated effects were present independent of this pretreatment with ASA. Following stimulation with collagen a synergistic effect of Mg and ASA was demonstrated on platelet aggregation. The platelet inhibiting effect demonstrated in this study may in part explain the beneficial effect of Mg infusion in some patients with acute myocardial infarction. The effect of Mg infusion, given alone or administered simultaneously with ASA, should also be evaluated in other arterial thrombotic disease states.
Insights
Magnesium (Mg) effectively inhibits platelet aggregation and release functions in a dose-dependent manner. These antiplatelet effects of magnesium are independent of acetylsalicylic acid (ASA) and may explain its benefits in acute myocardial infarction.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Hematology
Background:
- Platelet aggregation plays a crucial role in arterial thrombosis.
- Magnesium's potential role in cardiovascular health is under investigation.
- Understanding magnesium's effect on platelet function is essential for therapeutic applications.
Purpose of the Study:
- To investigate the in vitro effects of magnesium sulfate (MgSO4) on platelet aggregation and release functions.
- To determine if magnesium's antiplatelet effects are influenced by acetylsalicylic acid (ASA) pretreatment.
- To explore the potential clinical implications of magnesium's antiplatelet activity.
Main Methods:
- In vitro evaluation of magnesium sulfate (0.5-8.0 mM) on platelet aggregation induced by collagen, ADP, or thrombin.
- Assessment of platelet synthesis of thromboxane A2 and release of beta-thromboglobulin.
- Comparison of magnesium's effects with and without prior low-dose acetylsalicylic acid (ASA) administration in healthy volunteers.
Main Results:
- Magnesium demonstrated dose-dependent inhibition of platelet aggregation across various media and agonists.
- Significant inhibition was observed starting at 1.0 mM MgSO4.
- Magnesium inhibited thromboxane A2 synthesis and beta-thromboglobulin release.
- Magnesium's antiplatelet effects were independent of ASA pretreatment.
- Synergistic antiplatelet effects were noted between magnesium and ASA upon collagen stimulation.
Conclusions:
- Magnesium exhibits significant in vitro antiplatelet activity, inhibiting both aggregation and release functions.
- These magnesium-mediated effects are dose-dependent and occur independently of ASA.
- The findings suggest magnesium's antiplatelet properties may contribute to its beneficial effects in acute myocardial infarction.
- Further research into magnesium's role in arterial thrombotic diseases, alone or with ASA, is warranted.